Human parvovirus B19 associated dilated cardiomyopathy

Jain, Parul; Khan, Danish Nasar; Kumar, Madhu

doi:10.1136/bcr-2013-010410

Cited by 17 publications

(21 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Genotype 3 has been reported only sporadically from Asia [Abe et al, ]. The authors have also identified Genotype 3 of B19V from two cases of myocarditis [Jain et al, ]. Until recently, genotype 3 was thought to be restricted to West Africa [Hubschen et al, ].…”

Section: Discussionmentioning

confidence: 99%

Prevalence and genotypic characterization of human parvovirus B19 in children with hemato‐oncological disorders in North India

Jain

Prakash

Khan

et al. 2014

Journal of Medical Virology

View full text Add to dashboard Cite

Human parvovirus B19 (B19V) has been associated with chronic anemia in immuno-compromised patients. In the present study, the prevalence and genotype distribution of B19V in children from North India, suffering with hemato-oncological disorders is reported. Children with aplastic anemia/leukemia/chronic hematological disorders, and healthy blood donors were enrolled in the study. Blood samples from cases and blood donors were analyzed for anti-B19V IgM and anti-B19V IgG antibodies by ELISA and for B19V-DNA by PCR. B19V-DNA positive samples were studied further for determination of viral load in samples and for B19V-DNA sequence (VP1/VP2 overlapping region) analysis. Total 238 cases (103 leukemia, 77 aplastic anemia and 58 chronic hematological disorders) and 350 blood donors were enrolled in the study. Anti-B19V IgM was positive in 16 (6.7%) cases, B19V-DNA was detected in 13 (5.5%) cases and anti-B19V IgG was positive in 127 (53.4%) cases. Total 223 (63.5%) blood donors were positive for anti-B19V IgG, however, anti-B19V IgM and B19V-DNA was not detected in any blood donor. The prevalence of anti-B19V IgG was significantly higher in children > 10 years of age. Viral load of B19V decreased with appearance of specific antibodies. Phylogenetic analysis of the VP1/VP2 overlapping region revealed that genotype 1 predominated in these patients (11/13, 84.6%), followed by genotype 3 (2/13, 15.4%). No genotype 2 was detected. All the genotype 1strains were sub-typed as 1a, except four strains, which matched neither 1a nor 1b and formed a separate cluster. Both the genotype 3 strains were sub-typed as 3b.

show abstract

Section: Discussionmentioning

confidence: 99%

Prevalence and genotypic characterization of human parvovirus B19 in children with hemato‐oncological disorders in North India

Jain

Prakash

Khan

et al. 2014

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

“…Therefore, it is not surprising that investigators have detected B19V DNA in various percentages of patients with myocarditis (192,853,854), pediatric heart transplant recipients (855), and cases of dilated cardiomyopathy (853,856). The presence of replicative intermediate B19V DNA forms (857)(858)(859) and B19V capsid protein in biopsy specimens has been reported (860), but B19V viral loads have not correlated with outcomes (861). Myositis affecting muscles other than the heart is rarely associated with B19V (798).…”

Section: Clinical Manifestations Diseases Caused By B19v Infectionmentioning

confidence: 99%

Human Parvoviruses

2017

View full text Add to dashboard Cite

Parvovirus B19 (B19V) and human bocavirus 1 (HBoV1), members of the large Parvoviridae family, are human pathogens responsible for a variety of diseases. For B19V in particular, host features determine disease manifestations. These viruses are prevalent worldwide and are culturable in vitro, and serological and molecular assays are available but require careful interpretation of results. Additional human parvoviruses, including HBoV2 to -4, human parvovirus 4 (PARV4), and human bufavirus (BuV) are also reviewed. The full spectrum of parvovirus disease in humans has yet to be established. Candidate recombinant B19V vaccines have been developed but may not be commercially feasible. We review relevant features of the molecular and cellular biology of these viruses, and the human immune response that they elicit, which have allowed a deep understanding of pathophysiology.

show abstract

“…Genotype 3 was thought to have a restricted distribution, but is recently being reported from various countries, which may be due to improved diagnostic assays or increased spread of the virus [Hubschen et al, ]. The authors have earlier detected genotypes 1 and 3b of B19V in cases of myocarditis [Jain et al, ] and in children with hematological malignancies [Jain et al, ] in North India. The present study detected only genotype 3b of B19V in children receiving chemotherapy for solid tumors at a tertiary care hospital within a defined time period.…”

Section: Discussionmentioning

confidence: 99%

Genotype 3b of human parvovirus B19 detected from hospitalized children with solid malignancies in a North Indian tertiary care hospital

et al. 2016

View full text Add to dashboard Cite

Human parvovirus B19 (B19V) infection is known to cause serious consequences in immuno-compromized individuals. The present cross sectional study was designed to estimate the prevalence and genotype distribution of B19V in children receiving chemotherapy for solid malignancies at a tertiary care hospital in North India during October 2013 to May 2015. Serum samples from all the patients were tested for anti-B19V IgM and IgG antibodies and for B19V-DNA as soon as received. Samples testing positive for B19V-DNA were subjected to viral load estimation and to genotype determination by sequencing. Total 96 children were enrolled of which 9 (9.3%), 32 (33.3%), and 25 (26%) tested positive for anti-B19V IgM, anti-B19V IgG, and B19V-DNA, respectively. The viral load of B19V-DNA positive children ranged from 5.5 × 10(2) to 3.5 × 10(12) copies/ml. Accordingly children were divided into three groups: group I, with acute infection (n = 25); group II, previously exposed (n = 27), and group III, negative for B19V infection or with inappropriate antibody response (n = 44). B19V positivity was significantly associated (P-value < 0.0001) with a history of blood transfusion in the past 6 months, severe anemia (hemoglobin levels <6 gm%) and thrombocytopenia (platelets <150,000/cu.mm.). Sequence analysis of 21 of 25 DNA positive samples showed that all of them were Genotype 3b that clustered into three groups. All the sequences within each cluster were identical. The nucleotide identity of the sequences suggests a nosocomial outbreak of B19V during the study period. Children on chemotherapy for solid tumors should be routinely screened for B19V infection by both serology and PCR. J. Med. Virol. 88:1922-1929, 2016. © 2016 Wiley Periodicals, Inc.

show abstract

Human parvovirus B19 associated dilated cardiomyopathy

Cited by 17 publications

References 9 publications

Prevalence and genotypic characterization of human parvovirus B19 in children with hemato‐oncological disorders in North India

Prevalence and genotypic characterization of human parvovirus B19 in children with hemato‐oncological disorders in North India

Human Parvoviruses

Genotype 3b of human parvovirus B19 detected from hospitalized children with solid malignancies in a North Indian tertiary care hospital

Contact Info

Product

Resources

About